Canada markets closed

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1880-0.0076 (-3.89%)
At close: 04:00PM EST
0.1864 -0.00 (-0.85%)
After hours: 07:25PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1956
Open0.1800
Bid0.1881 x 1000
Ask0.1963 x 1200
Day's Range0.1800 - 0.1900
52 Week Range0.1500 - 1.7200
Volume150,828
Avg. Volume932,193
Market Cap7.259M
Beta (5Y Monthly)0.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates. “The Company had several notable deliverables this quarter and continues to focus on progressing its planned development of istaroxime. The positive results of the SEISMiC study o

  • GlobeNewswire

    Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

    Anticipated New Patent Will Add to the Istaroxime Patent Estate and Provide Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of new patent claims for istaroxime administration. A not

  • GlobeNewswire

    Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

    WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629). Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the b